Since paraneoplastic neurologic syndromes remain underrecognized in oncology, experts recently discussed diagnostic challenges, treatment strategies, and the need for clinical vigilance.
As advances in oncology continue to extend survival across many tumor types, clinicians are increasingly encountering complex neurologic complications that arise alongside cancer and its treatment. Among the most challenging of these conditions are paraneoplastic neurologic syndromes (PNS), a group of immune-mediated neurologic disorders that occur as indirect effects of malignancy rather than direct tumor invasion of the nervous system.1 Although rare, these syndromes can present with diverse and often subtle neurologic symptoms that may initially be difficult to distinguish from treatment-related toxicities or other complications of cancer care.
As
Similarly,
PNS develop when the immune system mounts an antitumor response that cross-reacts with neuronal antigens, producing inflammation and dysfunction within the central or peripheral nervous system.1,2 These syndromes can affect multiple neurologic domains, including cognition, movement, sensory pathways, and autonomic regulation, and may progress rapidly if not recognized early.2
Although considered rare, PNS represents an important diagnostic consideration in oncology practice. Contemporary epidemiologic analyses suggest that paraneoplastic neurologic disorders occur in approximately 1 in 300 patients with cancer, although population-level studies report incidence rates of roughly 1.6 to 8.9 per million person-years, indicating that the condition likely remains underrecognized in clinical practice.2,3
One of the most significant challenges in diagnosing PNS lies in the broad differential diagnosis of neurologic symptoms in patients with cancer. Neurologic deficits may arise from a range of causes, including direct tumor involvement of the nervous system, treatment-related toxicity, metabolic abnormalities, infection, or vascular complications.1
“PNS are immune-mediated and require a fundamentally different treatment approach. Missing this distinction has significant clinical implications,” Prindahl added in the conversation. “As such, if there is any concern that the presentation is atypical or inconsistent with expected treatment-related toxicity, clinicians should maintain a low threshold for further diagnostic evaluation, as management strategies differ substantially.”
Before clinicians can attribute neurologic symptoms to a paraneoplastic process, more common etiologies must be excluded. Brain metastases, leptomeningeal disease, and treatment-related neurologic adverse effects remain far more frequent explanations for neurologic symptoms in oncology populations.1
Neuroimaging and cerebrospinal fluid analysis are typically used to evaluate potential structural or inflammatory causes of neurologic dysfunction. In addition, serologic testing for onconeural antibodies can provide important diagnostic clues, particularly when clinical features are consistent with known paraneoplastic syndromes.2 Antibodies such as anti-Hu, anti-Yo, anti-Ri, and others have been associated with specific neurologic phenotypes and tumor types, although antibody testing alone does not establish the diagnosis.2
Because neurologic symptoms may precede the identification of an underlying malignancy, clinicians may also need to pursue extensive cancer screening when PNS is suspected.1
The rapid expansion of systemic cancer therapies has further complicated the diagnostic landscape. Many agents, including cytotoxic chemotherapy, targeted therapies, and immunotherapies, can produce neurologic adverse effects that overlap with the clinical manifestations of PNS.4
“Essentially, chemotherapy-induced toxicity refers to relatively well-characterized complications that occur within a predictable time frame following drug administration,” Shah explained in the discussion. “These toxicities are generally well understood; for example, certain agents are known to cause painful peripheral neuropathy, whereas others may be more likely to induce cerebral edema. With this knowledge, clinicians can more effectively narrow the differential diagnosis and identify the most likely cause of a patient’s neurologic presentation.”
Peripheral neuropathy associated with platinum-based chemotherapy or taxanes may mimic sensory neuropathies observed in paraneoplastic disorders. Similarly, immune checkpoint inhibitors (ICIs) can produce a range of immune-mediated neurologic complications, including encephalitis, neuropathies, and neuromuscular disorders.4,5
This overlap between treatment-related toxicity and paraneoplastic disease presents a major diagnostic challenge. Symptoms such as fatigue, weakness, and cognitive changes, common among patients receiving systemic therapy, may obscure early neurologic manifestations of PNS.
Management of PNS generally focuses on 2 parallel therapeutic priorities, including treatment of the underlying malignancy and suppression of the autoimmune response affecting the nervous system.2 Control of the primary tumor is often central to managing paraneoplastic disease, as the immune response driving neurologic injury is typically triggered by tumor-associated antigens.2
At the same time, immunomodulatory therapies may be used to limit ongoing neurologic damage. Common treatment approaches include corticosteroids, intravenous immunoglobulin (IVIG), and plasma exchange, although the effectiveness of these interventions varies depending on the specific syndrome and antibody profile.2
In selected cases, additional immunosuppressive agents such as rituximab or cyclophosphamide may be considered, particularly when symptoms continue to progress despite initial therapy.2 Early recognition remains a key determinant of neurologic outcomes, as delayed diagnosis may lead to irreversible neuronal injury.2
The widespread adoption of immunotherapy across oncology has renewed attention to immune-mediated neurologic complications, including PNS. The introduction of immune checkpoint inhibitors has been associated with an expanding spectrum of neurologic autoimmune disorders that can resemble or overlap with paraneoplastic syndromes.5
“Any neurologic symptoms that are progressively worsening—regardless of time course or whether a patient has a known cancer diagnosis should prompt a low threshold for early diagnostic evaluation,” Primdahl added during the conversation. “This includes testing in both the serum and the central nervous system, particularly through cerebrospinal fluid analysis, to assess for a potential paraneoplastic etiology.”
If clinicians are not comfortable performing or interpreting this workup, referral to a specialist with expertise in PNS is appropriate and encouraged. Early diagnosis and treatment are critical, as timely intervention may improve neurologic function and overall patient outcomes.
For clinicians, this evolving therapeutic landscape underscores the importance of distinguishing between paraneoplastic syndromes and treatment-related immune toxicities. Continued collaboration between neurologists, oncologists, and neuro-oncology specialists will be essential to improving recognition and outcomes for patients affected by these rare but potentially devastating complications.
